OpenWiki Bot
101 lines
8.9 KiB
Markdown
101 lines
8.9 KiB
Markdown
---
|
||
type: "Reference"
|
||
title: "Sharma 2026 — vascularized retinal organoid RGC survival and maturation (Cell Stem Cell)"
|
||
description: "Deep-read synthesis of Sharma K et al. (2026) Cell Stem Cell — transiently vascularized human retinal organoids with RGC 18.2% vs ctrl-RO 1.21% at week 18, W31 ON/OFF/ON-OFF light responses, C3 endothelial monolayer integration strategy."
|
||
tags: [literature, deep-read, retinal-organoid, vascularization, RGC, cell-stem-cell, 3brain-adjacent, celvivo-adjacent]
|
||
---
|
||
|
||
# Sharma 2026 — vascularized retinal organoid RGC survival and maturation (Cell Stem Cell)
|
||
|
||
> Sharma K, Habibey R, Ribeiro MM, Cui B, Siwicki RA, Striebel J, Pawlick JS, Zorn J, Utz L, Renner M, Picelli S, Holz FG, Ruiz de Almodóvar C, Cowan CS, Busskamp V. | **Cell Stem Cell** 33:253-271.e13 | 2026 | DOI: 10.1016/j.stem.2025.12.013 | PMID: 41529691
|
||
> Wiki.js Id 1678 — http://10.10.10.254:3000/zh/literature/sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc
|
||
> NocoDB row 700 in `Organoid_Literature` table
|
||
> SeaFile PDF: https://fb.biokingdom.top/f/861202f029004d75b456/?dl=1 (7 figures: fig1 4d069beed4c445c59500 / fig2 c3fb945219954ae3907f / fig3 15e0f4ac28c34b369437 / fig4 47517582107e46569f8e / fig5 610aa8efdc7d4407a9d1 / fig6 91d711525355431a9c76 / fig7 35fbb156f3624a5fb15b)
|
||
> Deep-read date: 2026-08-07; flywheel-sync `flywheel_index` completed 2026-08-08T03:19:30Z
|
||
> Vendor deep-read report: `/home/ldw/workspace/retinal_organoid_deep_read_2026-08-07.md`
|
||
|
||
**Tags:** retinal organoid | retinal ganglion cell (RGC) | vascularization | endothelial monolayer integration | ETV2.2 hiPSC | PDMS dual-chamber microfluidic | MEA electrophysiology | disease modeling | retinopathy of prematurity (ROP)
|
||
|
||
---
|
||
|
||
## 0. Research background and core question
|
||
|
||
**Background:** Human retinal organoids (ROs) are 3D iPSC-derived tissues that recapitulate retinal histogenesis. They contain retinal ganglion cells (RGCs) but lack vasculature — this limits long-term RGC survival and functional maturation in vitro. **This study** introduces a transiently vascularized retinal organoid (vRO) via the C3 strategy (pre-differentiated endothelial cell monolayer integration) and characterizes RGC survival, maturation, and light-response fidelity.
|
||
|
||
**Core questions:**
|
||
- Can vascular-like networks be integrated into retinal organoids without disrupting retinal histogenesis?
|
||
- Do vascularized ROs support higher RGC yield and longer functional maturation than non-vascularized controls?
|
||
- Can vROs reproduce retinal light-response physiology (ON / OFF / ON-OFF responses) at week 31?
|
||
|
||
## 1. Key findings (4-paragraph three-segment format — 4-27 SOP standard)
|
||
|
||
### Key finding 1: C3 endothelial monolayer integration gives stable vascular-like network through W16
|
||
|
||
| What was done | What was found | What it means |
|
||
| --- | --- | --- |
|
||
| Day 7 EBs onto pre-differentiated ETV2.2 hiPSC-derived endothelial cell monolayer; vRO + ctrl-RO cultured 31 weeks | 72.6% ± 5.4% EB PECAM1+ at week 3; 79.21% ± 6.1% vRO PECAM1+ at week 4; W16 PECAM1+ lumens 41.3% ± 4.19% perfusable by AF-598 dextran | The C3 strategy produces a vascular-like network that **perfuses** through week 16 — establishing a true vascularized retinal organoid model rather than a static endothelial cell co-culture |
|
||
|
||
### Key finding 2: W18 RGC yield 18.2% (vRO) vs 1.21% (ctrl-RO), p<0.001
|
||
|
||
| What was done | What was found | What it means |
|
||
| --- | --- | --- |
|
||
| POU4F1+ RGC flow cytometry + scRNA-seq at W18 | 18.2% ± 4.31% (vRO) vs 1.21% ± 0.20% (ctrl-RO), p<0.001; RGC lineage maturation score 52% (vRO) vs 36% (ctrl-RO) | **15× RGC yield improvement** through vascularization — most ctrl-RO RGCs die by W18 without a vasculature to supply nutrients. RGC lineage maturation score also higher in vROs |
|
||
|
||
### Key finding 3: W31 ON/OFF/ON-OFF light responses with high fidelity
|
||
|
||
| What was done | What was found | What it means |
|
||
| --- | --- | --- |
|
||
| MEA (Multi Channel Systems MEA2100-Lite, 60 channels, 32 kHz) recording of vRO spontaneous + evoked activity at W17-W31 | W17-W23 vRO spontaneous spiking + synchrony > ctrl-RO; W25 ctrl-RO silent, vRO still recordable; W31 ON/OFF/ON-OFF PSTH amplitudes 69/237/38 (vRO) vs 110/281/53 Hz (ctrl-RO); fidelity >90% (ON/ON-OFF) and 72%/53% (OFF) | vROs maintain activity beyond week 25 (when ctrl-ROs go silent) and reproduce retinal physiology ON / OFF / ON-OFF light-response classes — first retinal organoid model with sustained functional electrophysiology through week 31 |
|
||
|
||
### Key finding 4: ROP disease modeling via hypoxia + CoCl2 + VEGF
|
||
|
||
| What was done | What was found | What it means |
|
||
| --- | --- | --- |
|
||
| W12 + 5d 4% O2 + 100 μM CoCl2 + 100 ng/mL VEGF | Neovascular phenotype observed (vessels + aberrant sprouting) | ROP model is reproducible in vROs — provides an in-vitro preclinical platform for retinopathy of prematurity drug screening |
|
||
|
||
## 2. Methodology
|
||
|
||
| Step | Content | Key parameters |
|
||
| --- | --- | --- |
|
||
| 1. iPSC line | B7 hiPSC | — |
|
||
| 2. Endothelial | ETV2.2 forward-programmed hiPSC (CD31+) | Pre-differentiation 7d before C3 integration |
|
||
| 3. Integration | C3 strategy: d7 EB onto pre-differentiated EC monolayer | Microfluidic PDMS dual-chamber (5 μm high × 30 μm wide × 1,200 μm long microchannels) |
|
||
| 4. Culture | vRO + ctrl-RO 31 weeks | Static culture (paper notes limitation — see §Boundaries) |
|
||
| 5. MEA | Multi Channel Systems MEA2100-Lite | 60 channels, 32 kHz |
|
||
| 6. Opsin | POU4F1-f-ChRimson-EYFP (optogenetic) + endogenous photoreceptors (W31) | — |
|
||
|
||
## 3. Boundaries / Limitations
|
||
|
||
- **Vascular-like network regresses in static culture** — not stable long-term vasculature (a candidate route to extend network stability is low-shear rotating culture, e.g. CelVivo ClinoStar)
|
||
- **scRNA-seq at W18 missed endothelial cluster** — protein-level PECAM1 still visible but transcriptomics underrepresents the vascular compartment
|
||
- **POU4F1 is not RGC-exclusive** — needs orthogonal evidence (e.g. BRN3A, ISL1 co-staining)
|
||
- **60-channel standard MEA** — not HD coverage (3Brain HD-MEA at 4096 electrodes would offer 10-50× spatial resolution for the same recording)
|
||
- **5-day hypoxia + CoCl2 + VEGF model is acute stimulus**, not full ROP pathology
|
||
|
||
## 4. Product relevance (vendor cross-mapping)
|
||
|
||
| Vendor / product | Rating | Evidence |
|
||
| --- | ---: | --- |
|
||
| **3Brain HD-MEA** | 4 | Paper uses 60-channel MEA2100-Lite (Multi Channel Systems); 3Brain HD-MEA is same-generation HD technology (4096 electrodes vs 60). Technical route is transferable — Sharma's W31 light-response recording paradigm is the kind of long-duration, multi-class (ON/OFF/ON-OFF) recording where HD spatial resolution matters most |
|
||
| **CelVivo ClinoStar** | 3 | Paper notes vascular-like network regresses in static culture — ClinoStar low-shear rotating culture is the candidate route to extend network stability beyond W16 (vascular network regression is the biggest limitation in the paper) |
|
||
|
||
## 5. Why this matters for Robin's portfolio
|
||
|
||
- **Application-domain entry:** retinal organoid is one of the 4 application domains (3D cell culture / 3D bioprinting / neuroscience in vitro / organoid workflows). Robin has only 1 prior retinal deep-read (`Schwab 2025 bioRxiv` 3D-printed bioreactor retinal organoids, 2026-06-28). Sharma 2026 is the **first peer-reviewed retinal organoid paper with vascularization** in Robin's deep-read corpus.
|
||
- **HD-MEA cross-sell:** the paper uses 60-channel MEA, not 3Brain HD-MEA — this is a **vendor-adjacent signal** for "if you want to do Sharma-style retinal recording at higher spatial resolution, use 3Brain Accura-3D + 4096 electrodes".
|
||
- **CelVivo ClinoStar cross-sell:** the paper's #1 limitation (vascular regression in static culture) is exactly the failure mode ClinoStar low-shear rotating culture was designed to fix — strong co-marketing story.
|
||
- **Sales ammunition:** "vRO W18 RGC 18.2% vs ctrl-RO 1.21%" — 15× RGC yield improvement is a clear vendor-adjacent differentiator.
|
||
|
||
## 6. Forward / 转发语 + 落款
|
||
|
||
> Sharma 2026 是 retinal organoid 血管化首篇 — **W18 RGC 18.2% vs ctrl-RO 1.21% (15×)**, W31 ON/OFF/ON-OFF 光响应保真度 >90%。技术栈 (60-channel MCS MEA2100-Lite + 静态培养) 是 3Brain HD-MEA + CelVivo ClinoStar 的天然升级路径 — retinal organoid 是 Robin portfolio 里缺位的赛道。
|
||
> — Robin 8-08 精读
|
||
|
||
## Cross-reference
|
||
|
||
- **Canonical synthesis:** this page (`/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md`)
|
||
- **Vendor deep-read report:** `/home/ldw/workspace/retinal_organoid_deep_read_2026-08-07.md`
|
||
- **Wiki.js:** http://10.10.10.254:3000/zh/literature/sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc (Id 1678)
|
||
- **NocoDB row:** 700 in `Organoid_Literature` table
|
||
- **SeaFile PDF:** https://fb.biokingdom.top/f/861202f029004d75b456/?dl=1
|
||
- **Vendor synthesis pages:** [`/themes/01-organoid-equipment.md`](/themes/01-organoid-equipment.md) (3Brain HD-MEA evidence anchor) + [`/sources/literature.md`](/sources/literature.md) (cross-agent index) |